-
-
-
-
-
-
-
Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 52c, provides cash guidance
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Syros Pharmaceuticals (SYRS)
-
-
-
-
-
-
-
Form SC 13G/A Syros Pharmaceuticals, Filed by: ARK Investment Management LLC
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

